PlainRecalls
FDA Drug Moderate Class II Terminated

Ranitidine, 150 mg Tablets, a) 7 count, b) 14 count, c) 20 count, d) 30 count, e) 60 count; Rx, Only, H.J. Harkins Company, Inc. dba Pharma Pac Grover Beach, CA 93433 NDC #s: 52959-0502-07, 52959-0502-14, 52959-0502-20, 52959-0502-30 and 52959-0502-60

Reported: January 29, 2020 Initiated: January 6, 2020 #D-0793-2020

Product Description

Ranitidine, 150 mg Tablets, a) 7 count, b) 14 count, c) 20 count, d) 30 count, e) 60 count; Rx, Only, H.J. Harkins Company, Inc. dba Pharma Pac Grover Beach, CA 93433 NDC #s: 52959-0502-07, 52959-0502-14, 52959-0502-20, 52959-0502-30 and 52959-0502-60

Reason for Recall

CGMP Deviations: Presence of NDMA impurity detected in product.

Details

Units Affected
7,212 tablets
Distribution
Distributed to Physicians in the following states: CA, FL, NC, and SC.
Location
Grover Beach, CA

Frequently Asked Questions

What product was recalled?
Ranitidine, 150 mg Tablets, a) 7 count, b) 14 count, c) 20 count, d) 30 count, e) 60 count; Rx, Only, H.J. Harkins Company, Inc. dba Pharma Pac Grover Beach, CA 93433 NDC #s: 52959-0502-07, 52959-0502-14, 52959-0502-20, 52959-0502-30 and 52959-0502-60. Recalled by H J Harkins Company Inc dba Pharma Pac. Units affected: 7,212 tablets.
Why was this product recalled?
CGMP Deviations: Presence of NDMA impurity detected in product.
Which agency issued this recall?
This recall was issued by the FDA Drug on January 29, 2020. Severity: Moderate. Recall number: D-0793-2020.